PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New analysis shows tirzepatide consistently reduces bodyweight regardless of body mass index (BMI) before treatment

2024-03-13
(Press-News.org) *Note – this is an early press release from the European Congress on Obesity in Venice, Italy 12-15 May. Please credit the congress when using this research*

Tirzepatide, a medication authorised to treat obesity and/or type 2 diabetes, consistently reduces bodyweight regardless of the patient’s body mass index (BMI before treatment), from the range of overweight to class III obesity. The study, to be presented at this year’s European Congress on Obesity (Venice, Italy, 12-15 May) is by Prof Carel Le Roux, University College Dublin, Ireland, and Dr Louis J Aronne, Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, USA, and colleagues from Eli Lilly and Company, the manufacturer of tirzepatide.

Tirzepatide (Mounjaro®) was approved by the US Food and Drug administration (FDA) and the European Medicines Agency (EMA) for the treatment of type 2 diabetes in 2022. In November 2023, the FDA approved tirzepatide (Zepbound®) for chronic weight management in adults with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with at least one weight-related comorbidity.  Also in November 2023, the EMA Committee for Medicinal Products for Human Use offered a positive opinion on extension of the Mounjaro® label to include weight management in adults with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 and at least one weight-related comorbid condition.

This new analysis examined the impact of baseline body mass index (BMI) category on weight reduction in these trials. The phase 3 SURMOUNT trials examined the efficacy and safety of tirzepatide versus placebo in people with a BMI of 30 kg/m² and above or 27 kg/m² with at least one weight-related comorbidity without type 2 diabetes (SURMOUNT-1, 72 weeks), with type 2 diabetes (SURMOUNT-2, 72 weeks), and without type 2 diabetes after a 12-week intensive lifestyle intervention (SURMOUNT-3, 72 weeks from randomisation) or after an 88 week intervention (SURMOUNT-4, 36-week open label tirzepatide lead-in and 52 weeks following randomisation).

In this post-hoc subgroup analysis, BMI subgroups were defined by 27-30 (overweight), 30-35 (obesity class I), 35-40 (obesity class II), and 40 kg/m² and above (obesity class III). The authors examined the percent change in body weight from randomisation to week 72 (SURMOUNT-1, -2, and -3) or week 52 (SURMOUNT-4), as well as the proportions of participants achieving the weight reduction targets of 5, 10, and 15%. The analyses included all randomised participants who received 1 or more doses of the study drug (tirzepatide or placebo), excluding data after premature discontinuation of study drug.

The analysis showed that across SURMOUNT 1-4, tirzepatide treatment resulted in significant body weight reductions relative to placebo, irrespective of the BMI subgroup (see figure full abstract). In addition, more participants randomised to tirzepatide than placebo achieved the body weight reduction targets of 5, 10, and 15%. Across the BMI subgroups, up to 100% of tirzepatide-treated participants achieved weight reduction of 5% or more vs. 30% with placebo in SURMOUNT-1, up to 93% vs. 43% in SURMOUNT-2, and up to 97% vs. 15% in SURMOUNT-3.

The respective proportions achieving body weight reduction of at least 10% were up to 93% vs. 16% in SURMOUNT-1, up to 76% vs. 14% in SURMOUNT-2, and up to 92% vs. 8% in SURMOUNT-3.

Furthermore, up to 85% of participants achieved weight reduction of at least 15% with tirzepatide vs. 7% with placebo in SURMOUNT-1, up to 60% vs. 3% in SURMOUNT-2, and up to 78% vs. 4% in SURMOUNT-3.

In SURMOUNT-4, during the 36-week open-label tirzepatide treatment, the mean body weight reduction was 21%. After this lead-in period, further weight reductions of ≥5, ≥10, and ≥15% were achieved by up to 70%, 39%, and 22%, respectively, of participants treated with tirzepatide vs. 2%, 2%, and 0% with placebo.

“Regardless of baseline BMI, tirzepatide consistently reduced body weight versus placebo in people with obesity across the SURMOUNT 1-4 trials. Further analyses are needed to explore and understand why patients with type 2 diabetes have less weight loss in these trials than those without type 2 diabetes. Across the SURMOUNT 1-4 trials, treatment with tirzepatide, along with a reduced-calorie diet and increased physical activity, consistently resulted in clinically-significant weight reductions of 5% or more, 10% or more, or 15% or more, as compared to placebo, regardless of baseline BMI subgroup, in adults with obesity or overweight (BMI of 27 and above).” said Dr. Aronne.

Prof Le Roux added: “Tirzepatide is one of the most effective treatments we have for the disease of obesity, and not only can we control the disease but we are also able to disrupt the complications of obesity such as type 2 diabetes.”


 

END


ELSE PRESS RELEASES FROM THIS DATE:

Tirzepatide reduces body weight and waist circumference in people living with overweight or obesity regardless of duration of their condition

2024-03-13
*Note – this is an early press release from the European Congress on Obesity in Venice, Italy 12-15 May. Please credit the congress when using this research* New research to be presented at this year’s European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces bodyweight and waist circumference regardless of the length of time the person has been living with overweight or obesity. The study is by Dr Giovanna Muscogiuri, University of Naples Federico II, Naples, Italy, and colleagues. Tirzepatide (Mounjaro®) was approved by the US Food and ...

Scientists use novel technique to create new energy-efficient microelectronic device

Scientists use novel technique to create new energy-efficient microelectronic device
2024-03-13
Breakthrough could help lead to the development of new low-power semiconductors or quantum devices. As the integrated circuits that power our electronic devices get more powerful, they are also getting smaller. This trend of microelectronics has only accelerated in recent years as scientists try to fit increasingly more semiconducting components on a chip. Microelectronics face a key challenge because of their small size. To avoid overheating, microelectronics need to consume only a fraction of the electricity of conventional electronics while still operating at peak performance. Researchers at the U.S. Department of Energy’s (DOE) Argonne National Laboratory ...

Jay Sexton receives 2024 SEC Faculty Achievement Award

Jay Sexton receives 2024 SEC Faculty Achievement Award
2024-03-13
COLUMBIA, Mo. — In fourth grade, Jay Sexton first encountered one of James McPherson’s most influential works, “Battle Cry of Freedom: The Civil War Era.” That experience would ignite a lifelong passion for studying history and establish an ongoing legacy as a preeminent scholar in the study of the American story. As director of the Kinder Institute on Constitutional Democracy at the University of Missouri — a world-renowned academic center devoted to the study of the American founding, including constitutional ...

Canada Research Chair awarded to finance professor at the Rotman School of Management

Canada Research Chair awarded to finance professor at the Rotman School of Management
2024-03-13
Toronto – A leading academic expert in household finance, Claire Célérier, who is an associate professor of finance at the University of Toronto’s Rotman School of Management, has been named by the Government of Canada as the Canada Research Chair in Household Finance. Prof. Célérier’s research explores how finance can benefit households, investigating the role of innovation and the impact on diversity and inclusion. She addresses these questions taking different ...

Water droplet spun by sound screens for colon cancer

Water droplet spun by sound screens for colon cancer
2024-03-13
DURHAM, N.C. – Mechanical engineers at Duke University have devised a new type of diagnostic platform that uses sound waves to spin an individual drop of water up to 6,000 revolutions per minute. These speeds separate tiny biological particles within samples to enable new diagnostics based on exosomes. A very light disc placed on top of the spinning drop features etched channels that are equipped with star-shaped nanoparticles tailored to enable the label-free detection of specific disease-relevant bioparticles called exosomes. The technique ...

Study: Default testing for COVID-19 in K-12 schools more effective than voluntary testing

Study: Default testing for COVID-19 in K-12 schools more effective than voluntary testing
2024-03-13
CHAMPAIGN, Ill. — A new paper co-written by a team of University of Illinois Urbana-Champaign business professors found that default testing of K-12 students for COVID-19 during the pandemic could have saved up to one out of every five school days lost to the coronavirus during the fall 2021 semester. Schools adopting an “opt-out model” – in which students were regularly tested for COVID-19 unless they proactively declined or “opted out” of testing – experienced a 30% lower positivity rate than schools ...

Poor sleep linked to migraine attacks in new UArizona Health Sciences study

2024-03-13
A new study by researchers at the University of Arizona Health Sciences identified a link between poor sleep and migraine attacks that suggests improving sleep health may diminish migraine attacks in people with migraine. Many people with migraine report having sleeping disorders, including insomnia, trouble falling or staying asleep, poor sleep quality, excessive daytime sleepiness, waking up from sleep and being forced to sleep because of a migraine headache. Until now, it was unknown ...

Next generation stool DNA test has best detection rate of noninvasive colorectal cancer screening tools

2024-03-13
INDIANAPOLIS -- A study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas Imperiale, M.D., has found that the next generation multi-target stool DNA colorectal cancer screening test detects 94 percent of colorectal cancers. This test has the best performance for detection of both colorectal cancer and advanced precancerous polyps of any noninvasive colorectal cancer screening test. Study results are published in the New England Journal of Medicine. “We found that the next generation stool DNA test ...

Clinical study of a blood test shows 83% accuracy for detecting colorectal cancer

2024-03-13
SEATTLE — March 14, 2024 — A blood test intended for screening for colorectal cancer in people who are of average risk and not experiencing symptoms correctly detected colorectal cancer in 83% of people confirmed to have the disease, according to a study published March 14 in the New England Journal of Medicine. The accuracy rate for colorectal cancer is similar to at-home stool tests used for early detection of colorectal cancer. “The results of the study are a promising step toward developing more convenient tools to detect colorectal cancer early while it is more easily treated,” said corresponding ...

Preliminary clinical trial results show ‘dramatic and rapid’ regression of glioblastoma after next generation CAR-T therapy

Preliminary clinical trial results show ‘dramatic and rapid’ regression of glioblastoma after next generation CAR-T therapy
2024-03-13
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment. In a paper published today in The New England Journal of Medicine, researchers from the Mass General Cancer Center, a member of the Mass General Brigham healthcare system, shared the results for the first three patient cases from a phase 1 clinical trial evaluating a new approach to CAR-T therapy for glioblastoma (GBM). The trial, known as INCIPIENT, is designed to evaluate the safety of CARv3-TEAM-E T cells in patients with recurrent GBM. Just days after a single ...

LAST 30 PRESS RELEASES:

Resistance training may improve nerve health, slow aging process, study shows

Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer

SwRI-built instruments to monitor, provide advanced warning of space weather events

Breakthrough advances sodium-based battery design

New targeted radiation therapy shows near-complete response in rare sarcoma patients

Does physical frailty contribute to dementia?

Soccer headers and brain health: Study finds changes within folds of the brain

Decoding plants’ language of light

UNC Greensboro study finds ticks carrying Lyme disease moving into western NC

New implant restores blood pressure balance after spinal cord injury

New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows

Could a local anesthetic that doesn’t impair motor function be within reach?

1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5

In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day

Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds

Bronze and Iron Age cultures in the Middle East were committed to wine production

Indian adolescents are mostly starting their periods at an earlier age than 25 years ago

Temporary medical centers in Gaza known as "Medical Points" (MPs) treat an average of 117 people daily with only about 7 staff per MP

Rates of alcohol-induced deaths among the general population nearly doubled from 1999 to 2024

PLOS One study: In adolescent lab animals exposed to cocaine, High-Intensity Interval Training boosts aversion to the drug

Scientists identify four ways our bodies respond to COVID-19 vaccines

Stronger together: A new fusion protein boosts cancer immunotherapy

Hidden brain waves as triggers for post-seizure wandering

Music training can help the brain focus

Researcher develop the first hydride ion prototype battery

MIT researchers find a more precise way to edit the genome

‘Teen’ pachycephalosaur butts into fossil record

Study finds cocoa extract supplement reduced key marker of inflammation and aging

Obesity treatment with bariatric surgery vs GLP-1 receptor agonists

Nicotinamide for skin cancer chemoprevention

[Press-News.org] New analysis shows tirzepatide consistently reduces bodyweight regardless of body mass index (BMI) before treatment